Your Patients Are Paying Too Much for Striverdi — Here's How You Can Help

Cost is one of the most common reasons COPD patients don't fill their prescriptions — or stop taking them altogether. When a patient leaves your office with a prescription for Striverdi Respimat (Olodaterol) and arrives at the pharmacy to find a price tag of $275 to $400 for a one-month supply, adherence can fall apart before treatment even begins.

As a prescriber, you're in a unique position to help. Not by personally negotiating drug prices, but by integrating cost awareness into your prescribing workflow and connecting patients with the savings programs that already exist. This guide walks through the current pricing landscape for Striverdi and the tools available to help your patients afford their medication.

What Your Patients Are Actually Paying

Understanding the cost picture is the first step to addressing it effectively.

Cash Price

The retail cash price for Striverdi Respimat (2.5 mcg/actuation, one inhaler = 30-day supply) ranges from $275 to $400 depending on the pharmacy. There is no FDA-approved generic for Olodaterol as of 2026, which means patients without adequate insurance coverage face the full brand-name price.

Insurance Coverage Variability

Coverage for Striverdi varies significantly across payers:

• Commercial plans: Many cover Striverdi on a specialty or non-preferred brand tier, with copays ranging from $30 to $75+ depending on the plan's formulary structure
• Medicare Part D: Covered by many Part D plans, though patients may face varying copays depending on formulary tier and whether they've reached the coverage gap (donut hole)
• PBM exclusions: Some pharmacy benefit managers, including certain Express Scripts National Preferred Formulary plans, have excluded Striverdi Respimat in favor of alternative COPD inhalers. This means some of your commercially insured patients may face full cash pricing unless a formulary exception is approved
• Prior authorization and step therapy: Some plans require prior authorization or step therapy (trial of an alternative agent first) before approving Striverdi

The Adherence Impact

High out-of-pocket costs directly correlate with medication non-adherence in COPD. When patients can't afford their inhaler, they may skip doses, stretch the supply, or abandon the prescription entirely — leading to symptom exacerbation, increased ED visits, and hospitalizations. Proactive cost counseling at the point of prescribing can significantly improve fill rates and long-term adherence.

Manufacturer Savings Programs

Boehringer Ingelheim offers several programs that can meaningfully reduce patient costs:

Copay Savings Card

Boehringer Ingelheim provides a Copay Savings Card for eligible commercially insured patients. Key details:

• Available to patients with commercial (private) insurance
• Can significantly reduce copay or coinsurance amounts
• Striverdi participates in the $35 inhaler price cap initiative, which caps the monthly out-of-pocket cost for eligible patients
• Patients can enroll at patient.boehringer-ingelheim.com
• Not available to patients on Medicare, Medicaid, or other federal or state healthcare programs

Clinical staff can proactively print or share enrollment information at the point of prescribing to reduce friction.

Boehringer Cares Patient Assistance Program (PAP)

For patients who are uninsured or underinsured and meet income eligibility requirements, the Boehringer Cares Foundation provides Striverdi Respimat at no cost. Key details:

• Available to U.S. residents who lack insurance coverage for Striverdi or whose coverage leaves them unable to afford the medication
• Income-based eligibility criteria apply
• Application available at boehringer-ingelheim.com or by calling the manufacturer's patient support line
• Typically requires prescriber signature on the application

Consider designating a staff member or care coordinator to assist patients with PAP applications. The application process can be a barrier for patients who are older, less tech-savvy, or managing multiple chronic conditions.

Coupon Cards and Discount Platforms

For patients paying cash or facing high copays, third-party discount platforms can provide meaningful savings:

GoodRx

GoodRx aggregates pharmacy pricing and offers free coupons that can reduce the cash price of Striverdi at participating pharmacies. Patients can search at goodrx.com or use the mobile app to compare prices by pharmacy location.

SingleCare

SingleCare offers similar discount coupons for Striverdi Respimat. It integrates with many major pharmacy chains and can be used by patients regardless of insurance status.

Other Platforms

Additional options include RxSaver, Optum Perks, BuzzRx, and America's Pharmacy. These platforms all operate similarly — patients search for the drug, compare pharmacy pricing, and present a coupon at the point of sale.

Important note: Discount cards cannot be combined with insurance copays or manufacturer copay cards in most cases. They are most useful for cash-pay patients or those whose insurance doesn't cover Striverdi.

Therapeutic Alternatives When Cost Is Prohibitive

If cost remains a barrier despite available savings programs, consider discussing therapeutic alternatives with your patient:

Same-Class Alternatives (LABAs)

• Arcapta Neohaler (Indacaterol) — Once-daily LABA dry powder inhaler for COPD maintenance. May have different formulary coverage and pricing
• Serevent Diskus (Salmeterol) — Twice-daily LABA dry powder inhaler. Older agent but may be available at lower cost on some formularies
• Perforomist (Formoterol) — Twice-daily LABA delivered via nebulization. Option for patients who prefer or require a nebulizer

Combination Therapy

• Stiolto Respimat (Tiotropium/Olodaterol) — If your patient would benefit from dual bronchodilation (LAMA + LABA), this combination may offer better value than prescribing both agents separately. It uses the same Respimat device, so patients familiar with Striverdi will find the transition seamless

Formulary Navigation

When a patient's insurance excludes Striverdi, it's often because the PBM has a preferred COPD inhaler. Check the plan's formulary (or have your staff check) to identify which LABA or LABA/LAMA combination is preferred. Switching to the preferred agent often results in dramatically lower patient costs while maintaining clinical efficacy.

Workflow Tips for Your Practice

Integrating cost-of-care awareness into your prescribing workflow doesn't require a complete overhaul. Here are practical steps:

1. Check Formulary Coverage Before Prescribing

If your EHR has formulary integration, use it. A quick coverage check before sending the prescription can prevent the surprise at the pharmacy counter that leads to prescription abandonment.

2. Keep Savings Program Materials on Hand

Print or bookmark the enrollment links for:

• Boehringer Ingelheim Copay Savings Card (patient.boehringer-ingelheim.com)
• Boehringer Cares Patient Assistance Program
• GoodRx and SingleCare (for cash-pay comparisons)

Hand these to the patient at the time of prescribing — don't assume they'll find them on their own.

3. Designate a Cost Navigator

If you have a medical assistant, care coordinator, or social worker on staff, consider tasking them with helping patients navigate savings programs and PAP applications. This is especially impactful for elderly patients and those managing multiple chronic conditions.

4. Use Pharmacy Finder Tools

Direct patients to Medfinder to check which pharmacies near them have Striverdi in stock and compare pricing. This saves time for both the patient and your staff, and ensures the patient can actually fill the prescription.

5. Follow Up on Fill Rates

Consider tracking whether patients fill their initial prescription. If a patient doesn't fill within 7 to 10 days, a follow-up call or message can identify cost barriers early and give your team a chance to intervene with savings options or a therapeutic alternative.

6. Document Cost Discussions

Note in the patient's chart that you discussed cost and any savings programs offered. This supports continuity of care and ensures other providers on your team know what's been addressed.

Final Thoughts

The gap between writing a prescription and a patient actually filling it is often a financial one. For Striverdi Respimat, with its $275 to $400 cash price and variable insurance coverage, that gap can be significant. But the tools to bridge it exist — from manufacturer copay cards and patient assistance programs to discount platforms and formulary navigation.

By building cost awareness into your prescribing workflow, you're not just writing better prescriptions — you're improving adherence, reducing avoidable exacerbations, and ultimately delivering better COPD care.

For more resources, visit Medfinder for Providers to help your patients find Striverdi in stock and access real-time pharmacy availability.